Cargando…
SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use
Administration of an sodium–glucose cotransporter 2 inhibitor to individuals with insulin resistance reduces the level of glucose disposal necessary to maintain glycemia as a result of the induced increase in urinary glucose excretion. The amount of insulin required for a certain level of glucose di...
Autores principales: | Hosokawa, Yusei, Ogawa, Wataru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610101/ https://www.ncbi.nlm.nih.gov/pubmed/32469141 http://dx.doi.org/10.1111/jdi.13309 |
Ejemplares similares
-
New perspectives on insulin therapy
por: Araki, Eiichi, et al.
Publicado: (2020) -
Impaired insulin secretion and related factors in East Asian individuals
por: Nakamura, Akinobu, et al.
Publicado: (2021) -
Update on the efficacy and safety of sodium–glucose cotransporter 2 inhibitors in Asians and non‐Asians
por: Fujita, Yoshihito, et al.
Publicado: (2019) -
Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor‐related and conventional
por: Imagawa, Akihisa
Publicado: (2020) -
Dietary recommendations for type 2 diabetes patients: Lessons from recent clinical and basic research in Asia
por: Seino, Yusuke, et al.
Publicado: (2019)